Brian Cavanaugh - Musclepharm Corp Senior Vice President - Retail and Brand Strategy
| MSLPDelisted Stock | USD 0 0.0002 15.38% |
President
Brian Cavanaugh is Senior Vice President Retail and Brand Strategy of MusclePharm Corporationrationration. Cavanaugh comes to MusclePharm with a wealth of experience in the sports nutrition and wellness space with over 17 years of retail merchandising, product marketing, and brand development experience. Most recently, Cavanaugh served as Senior Vice President of Merchandising at GNC, managing all nutritional supplement categories encompassing 1.6 billion in revenue for the worldleading supplement retailer and manufacturer. For the past nine years, Cavanaugh worked in several capacities at GNC, advancing from Director of Sports Nutrition in 2006, to Senior VP of Merchandising in 2014 while meticulously establishing the industry standard for sports nutrition merchandising. Cavanaugh launched some of the biggest brands in the industry and played critical roles in developing and executing product strategies with more than 400 different suppliers to increase revenue and market share. He was a key part of the team that helped GNC deliver the number one IPO in 2011. since 2015.
| Tenure | 9 years |
| Phone | 800 859 3010 |
| Web | https://www.musclepharm.com |
Musclepharm Corp Management Efficiency
The company has return on total asset (ROA) of (0.665) % which means that it has lost $0.665 on every $100 spent on assets. This is way below average. Musclepharm Corp's management efficiency ratios could be used to measure how well Musclepharm Corp manages its routine affairs as well as how well it operates its assets and liabilities.The company currently holds 22.64 M in liabilities with Debt to Equity (D/E) ratio of 0.56, which is about average as compared to similar companies. Musclepharm Corp has a current ratio of 0.25, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Musclepharm Corp until it has trouble settling it off, either with new capital or with free cash flow. So, Musclepharm Corp's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Musclepharm Corp sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Musclepharm to invest in growth at high rates of return. When we think about Musclepharm Corp's use of debt, we should always consider it together with cash and equity.
Similar Executives
| Showing other executives | PRESIDENT Age | ||
| Christopher Barton | Hudson Pacific Properties | 54 | |
| Chris Gough | Edgewell Personal Care | N/A | |
| Joshua Hatfield | Hudson Pacific Properties | 46 | |
| Elizabeth Dreyer | Edgewell Personal Care | 54 | |
| Geoffrey Allman | Lincoln Electric Holdings | 53 | |
| Laura Campbell | Hudson Pacific Properties | N/A | |
| Daniel McMillIn | Lincoln Electric Holdings | N/A | |
| Dale Shimoda | Hudson Pacific Properties | 50 | |
| Michael Harris | Hooker Furniture | 59 | |
| George Blankenship | Lincoln Electric Holdings | 55 | |
| Andy Wattula | Hudson Pacific Properties | 48 | |
| Gretchen Farrell | Lincoln Electric Holdings | 51 | |
| Kevin Brown | MI Homes | N/A | |
| Douglas Lance | Lincoln Electric Holdings | 55 | |
| Mathias Hallmann | Lincoln Electric Holdings | 52 | |
| Chuck We | Hudson Pacific Properties | N/A | |
| Kay Tidwell | Hudson Pacific Properties | 47 | |
| Michael Delgatti | Hooker Furniture | 64 | |
| Anthony Bender | Edgewell Personal Care | 49 | |
| Steven Hedlund | Lincoln Electric Holdings | 57 | |
| Jennifer Ansberry | Lincoln Electric Holdings | 50 | |
Management Performance
| Return On Asset | -0.66 |
Musclepharm Corp Leadership Team
Elected by the shareholders, the Musclepharm Corp's board of directors comprises two types of representatives: Musclepharm Corp inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Musclepharm. The board's role is to monitor Musclepharm Corp's management team and ensure that shareholders' interests are well served. Musclepharm Corp's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Musclepharm Corp's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Peter Lynch, CFO, Principal Financial Officer, Principal Accounting Officer | ||
| Gary Shirshac, Interim Officer | ||
| William Bush, Director | ||
| Moore DSc, Chief Board | ||
| Stacey Jenkins, Director | ||
| Noel Thompson, Independent Director | ||
| Michael Doron, Independent Director | ||
| Brad Pyatt, Chairman of the Board, CEO | ||
| Matthew Kerbel, Chief Marketing Officer | ||
| Alberto Andrade, COO | ||
| Brian Cavanaugh, Senior Vice President - Retail and Brand Strategy | ||
| Brian Casutto, Executive Vice President - Sales and Operations, Director | ||
| John Price, CFO | ||
| Ryan Drexler, Executive Chairman | ||
| Mark Groussman, Consultant | ||
| Douglas West, Interim Principal Financial Officer, Interim Principal Accounting Officer | ||
| John Mills, Sr. Managing Director | ||
| John Desmond, Independent Director | ||
| Eric Chin, Chief Director |
Musclepharm Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Musclepharm Corp a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Asset | -0.66 | |||
| Profit Margin | (0.39) % | |||
| Operating Margin | (0.23) % | |||
| Current Valuation | 22.12 M | |||
| Shares Outstanding | 34.35 M | |||
| Shares Owned By Insiders | 53.50 % | |||
| Shares Owned By Institutions | 15.05 % | |||
| Price To Sales | 0 X | |||
| Revenue | 50.04 M | |||
| Gross Profit | 5.37 M |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of economic analysis. You can also try the Sectors module to list of equity sectors categorizing publicly traded companies based on their primary business activities.
Other Consideration for investing in Musclepharm Pink Sheet
If you are still planning to invest in Musclepharm Corp check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Musclepharm Corp's history and understand the potential risks before investing.
| Global Correlations Find global opportunities by holding instruments from different markets | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios |